Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070304 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00070304 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 33 participants.
The verdict
NCT00070304, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and vinorelbine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with vinorelbine works in treating young patients with recurrent or refractory Hodgkin's lymphoma.
Interventions
- BIOLOGICAL filgrastim
- DRUG gemcitabine hydrochloride
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2004-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070304
The ClinicalTrials.gov registry entry for NCT00070304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which filgrastim is the first listed.
NCT00070304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070304 about?
NCT00070304 is a clinical study titled "Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy, such as gemcitabine and vinorelbine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with ...
What is the current status of trial NCT00070304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2004-07.
What interventions are being tested in trial NCT00070304?
The interventions under investigation include: filgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00070304?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.